Evidence suggesting PSA cutpoint of 2.5 ng/mL for prompting prostate biopsy: Review of 36,316 biopsies

Urology

Volumn 65, Issue 3, 2005, Pages 549-553

  Gilbert, Scott M ^b   Cavallo, Christina B ^b   Kahane, Hillel ^b   Lowe, Franklin C ^a  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

BLOOD LEVEL; CANCER DIAGNOSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; REVIEW; SENSITIVITY AND SPECIFICITY; STANDARD;

EID: 15244361044     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urology.2004.10.064     Document Type: Article

References (22)

1. F.C. Lowe, S.M. Gilbert, H. Kahane Evidence of increased prostate cancer detection in men aged 50 to 59 a review of 324,684 biopsies performed between 1995 and 2002 Urology 62 2003 1045 1049
2. W.J. Catalona, D.S. Smith, T.L. Ratliff Measurement of prostate-specific antigen in serum as a screening test for prostate cancer N Engl J Med 324 1991 1156 1161
3. P.C. Walsh, A.W. Partin, J.I. Epstein Cancer control and quality of life following anatomical radical retropubic prostatectomy results at 10 years J Urol 152 1994 1831 1836
4. D.S. Smith, W.J. Catalona, J.C. Herschman Longitudinal screening for prostate cancer with prostate-specific antigen JAMA 276 1996 1309 1315
5. J.E. Oesterling, S.J. Jacobsen, C.G. Chute Serum prostate-specific antigen in a community-based population of healthy men establishment of age-specific reference ranges JAMA 270 1993 860 864
6. S.H. Woolf Screening for prostate cancer with prostate-specific antigen N Engl J Med 333 1995 1401 1405
7. W.J. Catalona, C.G. Ramos, G.F. Carvalhal Lowering PSA cutoffs to enhance detection of curable prostate cancer Urology 55 2000 791 795
8. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology, Prostate Cancer Early Detection, version 1.2004 2004 Available at: www.nccn.org. Accessed July 30
9. R.S. Punglia, A.V. D'Amico, W.J. Catalona Effect of verification bias on screening for prostate cancer by measuring prostate-specific antigen N Engl J Med 349 2003 335 342
10. W.J. Catalona, D.S. Smith, D.K. Ornstein Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/ml and benign prostate examination enhancement of specificity with free PSA measurements JAMA 277 1997 1452 1455
11. R.J. Babaian, D.A. Johnston, W. Naccarato The incidence of prostate cancer in a screening population with a serum prostate specific antigen between 2.5 and 4.0 ng/ml relation to biopsy strategy J Urol 165 2001 757 760
12. F.H. Schroder, I. van der Cruijsen-Koeter, H.J. de Koning Prostate cancer detection at low values of prostate-specific antigen (PSA) J Urol 163 2000 806 811
13. J. Krumholtz, G.F. Carvalhal, C.G. Ramos Total PSA cutoff of 2.5 correlates with favorable pathologic features of prostate cancer (abstract) J Urol 161 1999 99
14. J.S. Krumholtz, G.F. Carvalhal, C.G. Ramos Prostate-specific antigen cutoff of 2.6 ng/ml for prostate cancer screening is associated with favorable pathological features Urology 60 2002 469 474
15. I.M. Thompson, P.J. Goodman, C.M. Tangen The influence of finasteride on the development of prostate cancer N Engl J Med 349 2003 215 224
16. I.M. Thompson, D.K. Pauler, M.S. Goodman Prevalence of prostate cancer among men with prostate cancer-specific antigen level ≤4.0 ng per milliliter N Engl J Med 350 2004 2239 2246
17. R. Etzioni, D.F. Penson, J.M. Legler Overdiagnosis due to prostate-specific antigen screening lessons from U.S. prostate cancer incidence trends J Natl Cancer Inst 94 2002 981 990
18. G. Draisma, R. Boer, S.J. Otto Lead time and overdetection due to prostate-specific antigen screening estimates from the European Randomized Study of Screening for Prostate Cancer J Natl Cancer Inst 95 2003 868 878
19. H.J. de Koning, M. Liem, C.A. Baan Prostate cancer mortality reduction by screening power and time frame with complete enrollment in the European Randomized Screening for Prostate Cancer (ERSPC) trial Int J Cancer 98 2002 268 273
20. J.K. Gohagan, P.C. Prorok, R.B. Hayes The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute history, organization, and status Control Clin Trials 21 2000 251S 272S
21. W. Horninger, C.D. Cheli, R.J. Babaian Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliter Urology 60 suppl 4A 2002 31 35
22. A.W. Partin, M.K. Brawer, G. Bartsch Complexed prostate specific antigen improves specificity for prostate cancer detection results of a prospective multicenter clinical trial J Urol 170 2003 1787 1791